Drug profile · INN
pertuzumab
PERJETA
pertuzumab (PERJETA) is a receptor protein-tyrosine kinase erbb-2 inhibitor. Associated with Hoffmann-La Roche. Route of administration: single-use. Current US regulatory status: approved.
Drug details — pertuzumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- SINGLE-USE
- Patents
- 2
- Programs
- 22
- Data quality
- 0.84
Quick answer
pertuzumab (PERJETA) is a receptor protein-tyrosine kinase erbb-2 inhibitor. Associated with Hoffmann-La Roche. Route of administration: single-use. Current US regulatory status: approved.
Key facts
Mechanism of action
Receptor protein-tyrosine kinase erbB-2 inhibitor
Primary target: Receptor tyrosine-protein kinase erbB-2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is pertuzumab?
pertuzumab (PERJETA) is a receptor protein-tyrosine kinase erbb-2 inhibitor. Associated with Hoffmann-La Roche. Route of administration: single-use. Current US regulatory status: approved.
What is the brand name for pertuzumab?
PERJETA is a marketed brand name for pertuzumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pertuzumab?
pertuzumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.